Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.54 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316158 | 1.00 | HTR2C (0.72) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL3652770 | 0.88 | HTR2C (0.76) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL16467962 | 0.88 | HTR2C (0.76) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL31629096 | 0.88 | HTR2C (0.64) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL2391021 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL25635525 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL4431805 | 0.85 | HTR2C (0.72) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL8606286 | 0.84 | HTR2C (0.70) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL4677056 | 0.84 | HTR2C (1.00) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL154134 | 0.84 | HTR2C (0.55) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | HTR2C 347/4885CACNA1G 2/4885CACNA1H 3/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | HTR2C 347/4885CACNA1G 2/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.